PortalPublikationenCritical imbalance of TNF-α and soluble TNF receptor 1 in a ...

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.

Standard

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment. / Flammiger, Anna; Fiedler, Walter; Bacher, Ulrike; Bokemeyer, Carsten; Schneider, Marion; Binder, Mascha.

in: ACTA HAEMATOL-BASEL, Jahrgang 128, Nr. 2, 2, 2012, S. 69-72.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Flammiger, A, Fiedler, W, Bacher, U, Bokemeyer, C, Schneider, M & Binder, M 2012, 'Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.', ACTA HAEMATOL-BASEL, Jg. 128, Nr. 2, 2, S. 69-72. <http://www.ncbi.nlm.nih.gov/pubmed/22678422?dopt=Citation>

APA

Flammiger, A., Fiedler, W., Bacher, U., Bokemeyer, C., Schneider, M., & Binder, M. (2012). Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment. ACTA HAEMATOL-BASEL, 128(2), 69-72. [2]. http://www.ncbi.nlm.nih.gov/pubmed/22678422?dopt=Citation

Vancouver

Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M. Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment. ACTA HAEMATOL-BASEL. 2012;128(2):69-72. 2.

Bibtex

@article{12a00d35f6f1426cb615812a07d4391d,
title = "Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.",
abstract = "Macrophage activation syndrome (MAS) is a life-threatening disease with sustained activation of inflammatory cells and release of proinflammatory TNF-?. Under physiological conditions, TNF-? initiates a negative feedback mechanism, mediated by shedded, soluble TNF receptor ectodomains, eventually limiting the inflammatory reaction. Here, we report on a 27-year-old critically ill patient with refractory MAS and an insufficient negative feedback regulation, resulting in an overwhelming inflammatory response. A personalized treatment with soluble TNF receptor etanercept resulted in a durable remission. Further studies are warranted to establish whether the TNF cytokine profile may help to successfully guide patient selection for biological therapies.",
keywords = "Adult, Humans, Female, *Macrophage Activation, Receptors, Tumor Necrosis Factor/*blood, Tumor Necrosis Factor-alpha/*blood, Adult, Humans, Female, *Macrophage Activation, Receptors, Tumor Necrosis Factor/*blood, Tumor Necrosis Factor-alpha/*blood",
author = "Anna Flammiger and Walter Fiedler and Ulrike Bacher and Carsten Bokemeyer and Marion Schneider and Mascha Binder",
year = "2012",
language = "English",
volume = "128",
pages = "69--72",
journal = "ACTA HAEMATOL-BASEL",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

RIS

TY - JOUR

T1 - Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.

AU - Flammiger, Anna

AU - Fiedler, Walter

AU - Bacher, Ulrike

AU - Bokemeyer, Carsten

AU - Schneider, Marion

AU - Binder, Mascha

PY - 2012

Y1 - 2012

N2 - Macrophage activation syndrome (MAS) is a life-threatening disease with sustained activation of inflammatory cells and release of proinflammatory TNF-?. Under physiological conditions, TNF-? initiates a negative feedback mechanism, mediated by shedded, soluble TNF receptor ectodomains, eventually limiting the inflammatory reaction. Here, we report on a 27-year-old critically ill patient with refractory MAS and an insufficient negative feedback regulation, resulting in an overwhelming inflammatory response. A personalized treatment with soluble TNF receptor etanercept resulted in a durable remission. Further studies are warranted to establish whether the TNF cytokine profile may help to successfully guide patient selection for biological therapies.

AB - Macrophage activation syndrome (MAS) is a life-threatening disease with sustained activation of inflammatory cells and release of proinflammatory TNF-?. Under physiological conditions, TNF-? initiates a negative feedback mechanism, mediated by shedded, soluble TNF receptor ectodomains, eventually limiting the inflammatory reaction. Here, we report on a 27-year-old critically ill patient with refractory MAS and an insufficient negative feedback regulation, resulting in an overwhelming inflammatory response. A personalized treatment with soluble TNF receptor etanercept resulted in a durable remission. Further studies are warranted to establish whether the TNF cytokine profile may help to successfully guide patient selection for biological therapies.

KW - Adult

KW - Humans

KW - Female

KW - Macrophage Activation

KW - Receptors, Tumor Necrosis Factor/blood

KW - Tumor Necrosis Factor-alpha/blood

KW - Adult

KW - Humans

KW - Female

KW - Macrophage Activation

KW - Receptors, Tumor Necrosis Factor/blood

KW - Tumor Necrosis Factor-alpha/blood

M3 - SCORING: Journal article

VL - 128

SP - 69

EP - 72

JO - ACTA HAEMATOL-BASEL

JF - ACTA HAEMATOL-BASEL

SN - 0001-5792

IS - 2

M1 - 2

ER -